Markets are near all-time highs, and those who have missed the boat may be feeling a little bit of FOMO. While tech stocks have led the way for most of the year, it could be time for a change. John Gagliardi, Regional Brokerage Consultant at Fidelity, joined us to discuss strategies for dealing with the fear of missing out on the rally.
Tech stocks are the best performing names of the year, but the recent downturn in the group may be signaling a rotation into other sectors. Gagliardi keys in on Alcoa, a big time materials company that often kicks off earnings season. He uses technical analysis to express whether investors may have missed out on the stock’s massive jump higher. The stock’s 20% pull back could give investors another shot.
Gagliardi explains how to use technical patterns to make rational investment decisions. He uses a Fidelity tool to pinpoint the optimal times to get into a stock. He adds that by buying at several price points, it can help reduce investment risk and give an investor the chance to bring their average cost.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
